Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 3:16 PM
Ignite Modification Date: 2025-12-24 @ 3:16 PM
NCT ID: NCT04987892
Eligibility Criteria: Inclusion Criteria: 1. Male 45 years of age or older 2. Diagnosis of BPH 3. Experiencing symptoms of BPH as indicated by an IPSS ≥8 and ≤30 4. Willing to wash out of current BPH medication(s), as applicable 5. An appropriate candidate for both BPH therapies evaluated in this study. 6. Ability to understand and consent to participate in this study 7. Willing and able to participate in follow-up evaluations Exclusion Criteria: 1. Use of alpha blocker for BPH unless washed-out for 30 days 2. Use of daily phosphodiesterase type 5 inhibitor (PDE5i) for BPH unless washed-out for 30 days 3. 5-alpha-reductase inhibitors for BPH used within 6 months of therapy initiation 4. Current urinary tract infection or prostatitis 5. Current gross hematuria 6. Urinary incontinence presumed due to incompetent sphincter 7. Catheter-dependent urinary retention within 1 month prior to enrollment 8. Prostate volume greater than 100 cc as measured by TRUS 9. Prostate specific antigen level of greater than 10 ng/ml within one year of enrollment unless prostate cancer has been ruled out 10. History of neurogenic or atonic bladder 11. History prostate cancer treatment 12. Known to be hypersensitive to tamsulosin HCl or any component of tamsulosin HCl capsules 13. Known allergy to nickel, titanium, or stainless steel 14. Prior minimally invasive or surgical intervention for BPH 15. Urethral conditions that may prevent insertion of delivery system into bladder. 16. Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint 17. History of medical, surgical or other conditions that, in the opinion of the investigator, would interfere with the treatment or evaluation of the subject
Healthy Volunteers: True
Sex: MALE
Minimum Age: 45 Years
Study: NCT04987892
Study Brief:
Protocol Section: NCT04987892